ABOUT THE EXPERTS

Professor Dr. V. Khavinson is the Director of the St. Petersburg Institute of Bioregulation and Aging, North-Western Branch of the Russian Academy of Medical Sciences located in St. Petersburg, Russia.
Additionally, he is also:

• Vice-President of the Gerontological Society of the Russian Academy of Sciences
• Member of the Russian and Ukrainian Academies of Medical Sciences
• Advisor to the Committee for Social Policy of the Govt. of St. Petersburg, Russia

“And what is the main result? Main result…not one side effect. Not one allergic reaction, no side effects. Why?
Because our peptides are natural.”
Prof. Dr. V. Khavinson

Prof. Dr. Khavinson graduated from the S.M. Kirov Military Medical Academy with the rank of Colonel of the Military Medical Service in reserve.
His groundbreaking research interests are related to the development of the concept of peptide regulation of aging; the design, experimental and clinical study of peptide bioregulators; and elaboration of theoretical and practical grounds of bioregulation therapy and gerontology.

EXPERIENCE WITH REJUVEN-EYES BIO-THERAPY

Prof. Dr. Khavinson is the world’s foremost authority on the topic of peptide bioregulators. Since 1971, he has been engaged in studying the role of peptide bioregulators – including the components of Rejuven-Eyes Bio-Therapy – and their role in the regulation of aging mechanisms.

His unstinting efforts have resulted in the identification of a highly innovative novel method for the application of peptide bioregulators to slow down aging and increase average life span. These bioregulators include extracts and synthetic peptides which are copies of naturally occurring bioactive peptides.

To date, Dr. Khavinson has treated 15 million patients with his novel peptide therapies.

No less than 6 peptide pharmaceuticals and 36 biologically active supplements developed by Prof. Dr. Khavinson have been introduced into clinical practice. Additionally, he has over 600 research publications, including 25 monographs. He is also the author of 125 Russian and International patents.

ST. PETERSBURG INSTITUTE OF BIOREGULATION AND GERONTOLOGY

The St. Petersburg Institute of Bioregulation and Gerontology was established in 1992 and integrated into the North-Western Branch of the Russian Academy of Medical Sciences in 2001.

Its role is to introduce into medical practice the results of 20 years of experimental and clinical studies of peptide bioregulators, which were originally created in the Research Laboratory of Bioregulators of the S.M. Kirov Military Medical Academy.

The research activities of the St. Petersburg Institute of Bioregulation and Gerontology are related to:

• Study of improvement of methods for diagnosis and prognosis of various diseases, development of research, and production programs in bioregulation and gerontology.
• Design, clinical study, manufacture and introduction into the clinical practice of medications, state-of-the-art technologies of diagnostics, and therapy for the purpose of early diagnostics along with prevention and treatment of age-related pathologies.
• Propagation of research findings in the field of bioregulation and gerontology.

Professor Dr. S. Trofimova is the Director General of the Clinic of Predictive Medicine “The Tree of Life”, St. Petersburg Institute of Bioregulation and Aging, located in St. Petersburg, Russia.

Additionally, she is also –

• President of the Russian Society of Anti-Aging Medicine (RAAM)
• Deputy Director and Head Ophthalmologist, St. Petersburg Institute of Bioregulation and Gerontology
• Secretary-General. European Society of Preventive, Regenerative and Anti-Aging Medicine (ESAAM)

“After this treatment we see not only the stabilization of these pathological processes, but an improved functional activity of the retina. And that is why the visual acuity in our patients increases and the field of vision expands.”
Prof. Dr. S. Trofimova

Professor Dr. Trofimova graduated from St. Petersburg Pediatric Medical Academy in 1994 and obtained her Ph.D. in Medical Sciences with a Thesis in Ophthalmology entitled: “Application of Peptide Bioregulators in Diabetic Retinopathy”.
She obtained her M.D. degree in 2003.

EXPERIENCE WITH REJUVEN-EYES BIO-THERAPY

For the last 20 years Prof. Dr. Trofimova has been working in the research field of peptide regulation of aging as well as the experimental and clinical research of peptide bioregulators.

Along with Prof. Dr. Khavinson, she is one of the world leaders in peptide bioregulation and anti-aging medicine, along with her expertise on peptide therapy for degenerative retinal disorders – specifically Rejuven-Eyes Bio-Therapy.

In her own words: “We apply these peptides in patients with difficult diseases such as Retinitis Pigmentosa, age-related Macular Degeneration and Diabetic Retinopathy. We have 30 years of experience in treating these diseases.”

Along with investigating methods of assessment of quality of life and ways to achieve an active long life, Prof. Dr. Trofimova’s research interests also include studying the retinoprotective effect of peptide bioregulators in Age-Related Macular Diseases, Retinitis Pigmentosa, and Diabetic Retinopathy.

Prof. Dr. Trofimova has participated in numerous European and World Congresses on ophthalmology, gerontology and geriatrics and anti-aging medicine   and has over 150 scientific publications as well as 4 patents.

Dr. Ioannis Datseris is the Director of the OMMA Ophthalmological Institute located in Athens, Greece.

Additionally, he is also the President of the Greek Society of Ophthalmology.

“It is important to confirm that this peptide therapy is very safe. In my own experience, it has not caused any adverse effects in a single patient so far!”
Dr. I. Datseris

Dr. Datseris is a leading authority in the treatment of retinal degenerative diseases, who has dedicated his life in researching to finding treatment solutions for patients suffering from various forms of retinal degeneration – including macular degeneration, retinitis pigmentosa, and diabetic retinopathy.

As a result, he is in constantly sought out by other ophthalmologists and eye specialists who consult him regarding complex cases of retinal disorders.

When he’s not traveling to participate in ophthalmology meetings and events in Europe, the United States or Asia, Dr. Datseris spends his days meeting with his patients at OMMA – the realization of his ambitious vision for a center where comprehensive, cutting-edge diagnosis and treatment is offered to patients with glaucoma, cataracts, refractive disorders, myopia, hyperopia and many other eye disorders.

Such an ambitious scope requires highly specialized ophthalmologic expertise along with the latest in modern equipment. Dr. Datseris and OMMA fulfill both these requirements admirably.

Dr. Datseris is a member of the Board of the Medical Association of Athens. He obtained his University Diploma in Medicine at the University of Crete in 1991 and completed his Doctorate at the Department of Ophthalmology of the University of Crete in 2007. Dr. Datseris is certified by the European Board of Ophthalmology both as a practitioner and examiner.

In 1997, Dr. Datseris successfully completed the specialty examination in Ophthalmology supervised by Professor G. Theodossiadis, Dr. H. Feretis and Dr. N. Tsopelas offered at the University of Athens, Greece.

Dr. Datseris is currently an active member of the Panhellenic Ophthalmological Society, the American Academy of Ophthalmology, the International Society of Refractive Surgery and the European Society of Cataract and Refractive Surgeons.

EXPERIENCE WITH REJUVEN-EYES BIO-THERAPY

Under Dr. Datseris’ direct supervision at OMMA, several patients with dry Macular Degeneration and Retinitis Pigmentosa have been treated with the novel peptide therapy known as Rejuven-Eyes Bio-Therapy.

In his own words: “Over the past 5 years, we have treated patients with vision loss with a combination of small protein molecules known as peptides. The result of this peptide therapy is very encouraging!”

He’s right.

The results of a preliminary clinical study supervised by Dr. Datseris at OMMA show that a single course of treatment with Rejuven-Eyes Bio-Therapy noticeably increased sharpness of vision (known clinically as “visual acuity”) in patients with dry macular degeneration and retinitis pigmentosa.

According to Dr. Datseris: ”Not only is further vision loss prevented, many of these patients actually regain some of their lost vision!”